Henne-Bruns D, Marks H G, Marks V, Weh H J, Kremer B
Chirurgischen und Medizinischen, Universitätsklinik Hamburg.
Zentralbl Chir. 1989;114(10):668-76.
Experiences with different protocols of intraarterial chemotherapy in the treatment of primary or secondary liver malignancies in 38 cases were reported. The follow-up period was two years in all patients. Complications due to chemotherapy were observed only in very few patients. In 15 patients complications during chemotherapy from the implantable infusion system (Port a Cath) like leckage (n = 8), thrombosis of the system (n = 4), thrombosis of the hepatic artery (n = 1) and aneurysma of the hepatic artery (n = 2) occurred. Highest survival rates for the first and second year were achieved in patients with resectable liver metastases from colorectal cancer. A prophylactic implantation of an intraarterial catheter can be considered in patients in which a liver resection was performed because of multilocular uni- or bilateral metastases. CEA- and CA-19-9 levels did not correspond to the tumor progress in many cases.
报告了38例原发性或继发性肝脏恶性肿瘤患者采用不同动脉内化疗方案的治疗经验。所有患者的随访期均为两年。仅在极少数患者中观察到化疗相关并发症。15例患者在化疗期间出现了可植入输液系统（Port a Cath）相关并发症，如渗漏（8例）、系统血栓形成（4例）、肝动脉血栓形成（1例）和肝动脉瘤（2例）。结直肠癌肝转移可切除患者在第一年和第二年的生存率最高。对于因多房性单或双侧转移而进行肝切除的患者，可考虑预防性植入动脉内导管。在许多情况下，癌胚抗原（CEA）和糖类抗原19-9（CA-19-9）水平与肿瘤进展不相符。
